Outstanding questions in transplantation: Tolerance
- PMID: 31675469
- DOI: 10.1111/ajt.15680
Outstanding questions in transplantation: Tolerance
Abstract
In 2017, the American Society of Transplantation (AST) launched the Outstanding Questions in Transplantation Research forum to stimulate a community-wide discussion of how the field is evolving and to help identify areas where a better dialogue between clinicians and researchers could result in great advancements. Tolerance emerged as a topic of great interest to the AST community. This minireview provides an overview of clinical transplantation tolerance. Historical background followed by a review of the current status of attempts to establish tolerance in the clinic, highlighting the dynamic online discussion surrounding this important topic from the AST Transplantation Research forum, is provided.
Keywords: immunosuppression/immune modulation; stem cells; tolerance: chimerism; tolerance: clinical; tolerance: mechanisms; translational research/science.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
References
REFERENCES
- 
    - Helderman JH, Van Buren DH, Amend WJ Jr, Pirsch JD. Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol. 1994;4(8 Suppl):S2-S9.
 
- 
    - Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis. 2001;38(6 Suppl 6):S25-S35.
 
- 
    - Pirsch JD, D'Alessandro AM, Sollinger HW, et al. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol. 1992;2(12 Suppl):S238-S242.
 
- 
    - Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996;42(8 Pt 2):1316-1321.
 
- 
    - O'Riordan A, Wong V, McCormick PA, Hegarty JE, Watson AJ. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant. 2006;21(9):2630-2636.
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
 
        